US Patent

US9782376 — Levothyroxine liquid formulations

Formulation · Assigned to Fresenius Kabi USA LLC · Expires 2036-12-01 · 11y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a liquid formulation of levothyroxine or a pharmaceutically acceptable salt thereof, with specific ingredients and pH levels.

USPTO Abstract

The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.

Drugs covered by this patent

Patent Metadata

Patent number
US9782376
Jurisdiction
US
Classification
Formulation
Expires
2036-12-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Fresenius Kabi USA LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.